Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Mulligan, Jude M ^a   Hill, Laura A ^a   Deharo, Steve ^a   Irwin, Gareth ^b   Boyle, David ^b   Keating, Katherine E ^a   Raji, Olaide Y ^a   McDyer, Fionnuala A ^a   O'Brien, Eamonn ^a   Bylesjo, Max ^a   Quinn, Jennifer E ^b   Lindor, Noralane M ^c   Mullan, Paul B ^b   James, Colin R ^b   Walker, Steven M ^a   Kerr, Peter ^a   James, Jacqueline ^b   Davison, Timothy S ^a   Proutski, Vitali ^a   Salto Tellez, Manuel ^b   Johnston, Patrick G ^b   Couch, Fergus J ^d   Paul Harkin, D ^a,b   Kennedy, Richard D ^a,b   more..

^a Almac Sciences   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; FANCONI ANEMIA PROTEIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA DETERMINATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HEREDITY; HUMAN; HUMAN TISSUE; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG EFFECT; FANCONI ANEMIA; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RISK; VALIDATION STUDY;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DNA DAMAGE; DNA, NEOPLASM; EPIRUBICIN; FANCONI ANEMIA; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSPECTIVE STUDIES;

EID: 84892663597     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt335     Document Type: Article

References (43)

1. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483-2493.
2. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40(2):205-211.
3. Arun BK, Dhinghra K, Valero V, et al. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011;16(11):1527-1534.
4. Kriege M, Seynaeve C, Meijers-Heijboer H, et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(23):3764-3771.
5. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006;24(23):3799-3808.
6. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010;362(20):1909-1919.
7. Grompe M, D'Andrea A. Fanconi anemia and DNA repair. Hum Mol Genet. 2001;10(20):2253-9.
8. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005;19(24):2925-2940.
9. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer. 2004;4(10):814-819.
10. Vanderwerf SM, Svahn J, Olson S, et al. TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. Blood. 2009;114(26):5290-5298.
11. Tabchy A, Valero V, Vidaurre T, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010;16(21):5351-5361.
12. Iwamoto T, Bianchini G, Booser D, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011;103(3):264-272.
13. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 2007;8(12):1071-1078.
14. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-1474.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-410.
16. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13(11):3207- 3214.
17. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365(9460):671-679.
18. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262-272.
19. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29(35):4620-4626.
20. Tanney A, Oliver GR, Farztdinov V, et al. Generation of a nonsmall cell lung cancer transcriptome microarray. BMC Med Genomics. 2008;1:20.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Assoc. 1994;57(1):289-300.
22. Cho RJ, Huang M, Campbell MJ, et al. Transcriptional regulation and function during the human cell cycle. Nat Genet. 2001;27(1):48-54.
23. Yan M, Ye K. Determining the number of clusters using the weighted gap statistic. Biometrics. 2007;63(4):1031-1037.
24. DeJong S. SIMPLS: An alternative approach to partial least squares regression. Chemometrics Intell Lab Syst. 1993;18(3):251-263.
25. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39(2):499-503.
26. Sorlie T, Perou CM, Fan C, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 2006;5(11):2914-2918.
27. Clinical and Laboratory Standards Institute. Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 2008, Published by Clinical and Laboratory Standards Institute, Philadelphia, PA.
28. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113.
29. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003;63(19):6221-6228.
30. Linger RJ, Kruk PA. BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications. FEBS J. 2010;277(15):3086-3096.
31. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90(15):1138-1145.
32. Longacre TA, Ennis M, Quenneville LA, et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol. 2006;19(2):195-207.
33. Sabatel H, Pirlot C, Piette J, et al. Importance of PIKKs in NF-kappaB activation by genotoxic stress. Biochem Pharmacol. 2011;82(10):1371-1383.
34. Ignatiadis M, Singhal SK, Desmedt C, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol. 2012;30(16):1996-2004.
35. Mulligan AM, Raitman I, Feeley L, et al. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res. 2013;19(2):336-346.
36. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-1948.
37. Di Leo A, Desmedt C, Bartlett JM, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011;12(12):1134-1142.
38. Munro AF, Twelves C, Thomas JS, et al. Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. Br J Cancer. 2012;107(1):71-74.
39. Popova T, Manie E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72(21):5454-5462.
40. Daniels MJ, Wang Y, Lee M, et al. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science. 2004;306(5697):876-879.
41. Naim V, Rosselli F. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. Nat Cell Biol. 2009;11(6):761-768.
42. Rodriguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010;123(1):189-196.
43. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446- 1452.